<DOC>
	<DOCNO>NCT00815308</DOCNO>
	<brief_summary>The purpose study determine whether treatment locally advanced esophageal squamous cell carcinoma ( ESCC ) cetuximab combination paclitaxel , cisplatin radiation improve clinical outcome .</brief_summary>
	<brief_title>Erbitux Combined With Chemo-radiotherapy Esophageal Squamous Cell Carcinoma</brief_title>
	<detailed_description>Esophageal cancer sixth lead cause cancer death worldwide . Over past 2 decade , well-designed clinical trial document clinical benefit combination chemotherapy radiation localize esophageal cancer , either primary therapy neoadjuvant setting . Paclitaxel , radiation sensitizer , important single-agent activity esophageal cancer . Paclitaxel-based chemoradiation framework recent Radiation Therapy Oncology Group ( RTOG ) trial nonoperative management esophageal cancer . Accumulating clinical evidence suggest epidermal growth factor receptor ( EGFR ) represent viable target treatment esophageal cancer . EGFR expression associate poor prognosis . Cetuximab , monoclonal antibody , bind specifically EGFR normal tumor cell competitively inhibit bind EGF ligand , transform growth factor ( TGF ) -α. Preclinical model suggest synergy cetuximab , paclitaxel , cisplatin radiation . For patient locally advanced head neck cancer , combination cetuximab radiation demonstrate response survival benefit . With , investigator hypothesize treatment locally advanced esophageal squamous cell carcinoma ( ESCC ) cetuximab combination paclitaxel , cisplatin radiation may improve clinical outcome . This trial result important may support study set new treatment standard ESCC .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Inpatients outpatient , ≥ 18 year age Histologically confirm primary ( nonrecurrent ) ESCC fulfil one follow criterion ( AJCC Staging System ) cervical esophageal carcinoma , stage ⅡⅢ upper thoracic esophageal carcinoma , stage ⅡⅢ , midthoracic esophageal carcinoma , stage ⅡⅢ , medically unfit surgery , surgery refuse patient medically able tolerate chemoradiation . Evidence unidimensional measurable disease per Response Evaluation Criteria Solid Tumours ( RECIST ) . ECOG Performance status 01 Effective contraception male female patient risk conception exists Adequate bone marrow reserve : neutrophil ( ANC ) count ≥ 1500 /mm^3 , platelet count ≥ 100,000 /mm^3 , hemoglobin ≥ 9 g/dl Adequate renal function : serum creatinine ≤ 1.5 mg/dl and/or calculate creatinine clearance ≥ 60 ml/min Adequate hepatic function : bilirubin level ≤ 1.5 x ULN , ASAT &amp; ALST ≤ 1.5 x ULN Tumor tissue available KRAS biomarker test Signed write informed consent prior study entry Previous chest radiotherapy , systemic chemotherapy , major esophageal surgery Concurrent chronic systemic immune therapy , target therapy indicate study protocol Multiple primary carcinoma esophagus Pregnancy ( confirm serum urine βHCG ) lactation period ; Uncontrolled diabetes , hypertension , severe cardiac pulmonary disease Unable comprehend study requirement likely comply study parameter ; Distant metastasis Second malignancy , except curable nonmelanoma skin cancer , cervical cancer situ , malignant disease , free ≥ 5 year Known grade 3 4 allergic reaction study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Therapeutic</keyword>
	<keyword>Drug Therapy , combination</keyword>
	<keyword>Radiotherapy</keyword>
</DOC>